Search Results 161-170 of 17129 for egfr

  1. Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) - Mayo Clinic

    Participation eligibility · Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation; the testing ...

  2. A Study of Artificial Intelligence for Detection of High Potassium Levels in the Emergency Department Using Multilead ECG Devices - Mayo Clinic

    ... eGFR is not an exclusion criteria. KardiaK was trained and tested on ECGs from patients regardless of eGFR level, so we have no reason to believe the ...

  3. Clinical trials - Oncology (Medical)

    Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements ...

  4. A Study To Evaluate The Efficacy And Safety Of GDC-8264 In Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) And Major Adverse Kidney Events (MAKE) - Mayo Clinic

    ... eGFR < 60 milliliters/ minutes/ 1.73 meter square (ml/min/1.73 m^2) within the last 6 months, diabetes (type 1 or type 2) requiring at least one oral ...

  5. A Study to Evaluate the Addition of Immunotherapy into Adjuvant Therapy for Non-small Cell Lung Cancer - Mayo Clinic

    Participation eligibility · Individuals, ≥ 18 years of age. · Previously registered to A151216. · Central and/or local testing of EGFR with no EGFR exon 19 ...

  6. Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    Male and female subjects with eGFR between 25-65 mL/min/1.73m2 (if aged 18 to55) or eGFR between 25-44 mL/min/1.73m2 (if aged 56 to <66); Tolvaptan naïve ...

  7. A Study to Evaluate Safety and Effectiveness of Ganaxolone to Treat Status Epilepticus - Mayo Clinic

    (severe; eGFR 29-15 mL/min/1.73m2), or stage 5 (kidney failure; eGFR < 15 mL/min/1.73m2 or dialysis) kidney disease 11. Use of an investigational product ...

  8. Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) - Mayo Clinic

    ... (EGFR) monoclonal antibody. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

  9. An Open-label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations - Mayo Clinic

    ... EGFR gene-amplified solid tumors. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments ...

  10. A Study to Evaluate DS-1062a Combined with Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations - Mayo Clinic

    ... EGFR and ALK genomic alterations. Participants with squamous histology are required to undergo testing for EGFR and ALK genomic alterations if they are ...